Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 51 to 60 of 220 total matches.
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
(Margenza – MacroGenics), a HER2/neu receptor antagonist,
for use in combination with chemotherapy ...
The FDA has approved margetuximab-cmkb
(Margenza – MacroGenics), a HER2/neu receptor antagonist,
for use in combination with chemotherapy
for treatment of metastatic human epidermal growth
factor receptor 2 (HER2)-positive breast cancer in
adults who received ≥2 prior anti-HER2 regimens, at
least one of which was for metastatic disease.
Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
insertion
mutations in adults whose disease has progressed on
or after platinum-based chemotherapy ...
Mobocertinib (Exkivity – Takeda), an oral kinase
inhibitor, has received accelerated approval from the
FDA for treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) with epidermal
growth factor receptor (EGFR) exon 20 insertion
mutations in adults whose disease has progressed on
or after platinum-based chemotherapy. Accelerated
approval was based on the overall response rate and
duration of response. Mobocertinib is the second
drug to become available in the US for this indication;
the IV EGFR-MET bispecific antibody amivantamab
(Rybrevant) was approved...
PARP Inhibitors for Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
, recurrent
ovarian, primary peritoneal, or fallopian tube cancer
who had received ≥3 lines of chemotherapy ...
Three oral poly(ADP-ribose) polymerase (PARP)
inhibitors have been approved by the FDA for treatment
of advanced, recurrent ovarian cancer. Olaparib
(Lynparza – AstraZeneca), niraparib (Zejula – Tesaro),
and rucaparib (Rubraca – Clovis) are each approved
for somewhat different indications and for patients
with different biomarkers (see Table 2).
Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
cancer
(SCLC) in adults with disease progression on or after
platinum-based chemotherapy. Accelerated ...
The alkylating agent lurbinectedin (Zepzelca – Jazz)
has received accelerated approval from the FDA
for treatment of metastatic small-cell lung cancer
(SCLC) in adults with disease progression on or after
platinum-based chemotherapy. Accelerated approval
was based on the overall response rate and duration
of response. About 13-15% of lung cancers are small-cell
cancers. Most SCLCs occur in patients who are
current or former smokers.
Bone Marrow Transplants for Malignant Diseases
The Medical Letter on Drugs and Therapeutics • Aug 21, 1992 (Issue 877)
FOR
ONLINE USERS
BONE MARROW TRANSPLANTS FOR MALIGNANT DISEASES
Intensive chemotherapy, with or without ...
Intensive chemotherapy, with or without total body radiation, followed by bone marrow transplantation is now widely used in the treatment of malignant diseases. The drugs and radiation needed to try to eradicate the malignancy unavoidably destroy the bone marrow; intravenous infusion of bone marrow cells restores the marrow by repopulating it. Diseases for which bone marrow transplantation has been used include the leukemias and lymphomas, breast cancer, neuroblastoma, ovarian cancer, germ cell tumors, melanoma, multiple myeloma, and malignant gliomas (NC Gorin, Am J Clin On-col, 14...
A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
of diffuse large B-cell lymphoma, the
most common type of non-Hodgkin's lymphoma,
respond to chemotherapy ...
The FDA recently approved axicabtagene ciloleucel
(Yescarta – Kite), a CD19-directed genetically
modified cellular product, for treatment of large B-cell
lymphoma that is refractory to first-line chemoimmunotherapy
or that relapses within 12 months
of first-line treatment. It was previously approved for
treatment of relapsed or refractory B-cell lymphoma
after ≥2 lines of systemic therapy and for treatment
of relapsed or refractory follicular lymphoma
after ≥2 lines of systemic therapy. Yescarta is an
individualized cellular product prepared from the
patient's own T cells,...
In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 16, 2021 (Issue 1619)
in combination with chemotherapy
for neoadjuvant (preoperative) treatment of human
epidermal growth factor ...
The FDA has approved a fixed-dose combination of
pertuzumab, trastuzumab, and hyaluronidase (Phesgo – Genentech) for use in combination with chemotherapy
for neoadjuvant (preoperative) treatment of human
epidermal growth factor receptor 2 (HER2)-positive,
locally advanced, inflammatory, or early-stage breast
cancer, or for adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence,
or with docetaxel for treatment of those with HER2-positive metastatic breast cancer who have not received
anti-HER2 therapy or chemotherapy for metastatic
disease....
In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
treatment of adults with
unresectable or metastatic synovial sarcoma who
received prior chemotherapy ...
Afamitresgene autoleucel (Tecelra – Adaptimmune),
a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell
immunotherapy, has received accelerated approval
from the FDA for one-time treatment of adults with
unresectable or metastatic synovial sarcoma who
received prior chemotherapy and are HLA-A*02:01P,
-A*02:02P, -A*02:03P, or -A*02:06P positive and
whose tumor expresses the MAGE-A4 antigen. It is
the first gene therapy to be approved in the US for
treatment of synovial sarcoma. Accelerated approval
of the immunotherapy was based on the...
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e169-70 doi:10.58347/tml.2024.1713i | Show Introduction Hide Introduction
Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
or chemotherapy (docetaxel or vinflunine). After a
median follow-up of 15.9 months, overall survival ...
Erdafitinib (Balversa – Janssen), an oral kinase
inhibitor, has received full approval from the FDA
for treatment of locally advanced or metastatic
urothelial carcinoma in adults with susceptible
FGFR3 (fibroblast growth factor receptor) genetic
alterations who had disease progression on or after
at least one prior line of systemic therapy. It is not
recommended for use in patients who are eligible
for but have not received prior PD-1 (programmed
death receptor-1) or PD-L1 (programmed death-ligand
1) inhibitor therapy. Erdafitinib is the first
oral FGFR kinase inhibitor to be...
Med Lett Drugs Ther. 2024 May 13;66(1702):e83-4 doi:10.58347/tml.2024.1702g | Show Introduction Hide Introduction
In Brief: Intravenous Ondansetron (Zofran) 32 mg Withdrawn
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012 (Issue 1406)
that the single 32-mg IV dose of
ondansetron (Zofran, and generics) used for prevention of
cancer chemotherapy ...
The FDA has announced that the single 32-mg IV dose of ondansetron (Zofran, and generics) used for prevention of cancer chemotherapy-associated nausea and vomiting has been withdrawn from the market because it can prolong the QT interval and could possibly cause a torsades de pointes cardiac arrhythmia. For this indication, the only recommended dose of IV ondansetron is 0.15 mg/kg (maximum 16 mg/dose) every 4 hours for 3 doses. There are no changes in the recommended dosing regimens for oral ondansetron or for IV ondansetron used for prevention of postoperative nausea and vomiting.Download...